Vasa Therapeutics Receives FDA IND Clearance for VS-041 in Heart Failure with Preserved Ejection Fraction
核心洞察
Vasa Therapeutics (搜索) received FDA IND clearance for VS-041, a novel small molecule inhibitor of matrix metalloproteinases (搜索), to begin Phase 1c trials in HFpEF (搜索) patients.
The Phase 1c study will assess safety and tolerability of VS-041 in participants with HFpEF (搜索) and elevated serum endotrophin (搜索) levels.
VS-041 demonstrated robust reduction of cardiac fibrosis and significant improvement in diastolic heart function in preclinical HFpEF (搜索) models.
Vasa Therapeutics (搜索) announced that the U.S. Food and Drug Administration has cleared its Investigational New Drug application for VS-041, a narrow spectrum small molecule inhibitor of matrix metalloproteinases (搜索). The clinical-stage biotechnology company plans to immediately initiate a Phase 1c clinical trial in the United States for participants with Heart Failure with Preserved Ejection Fraction (搜索) (HFpEF (搜索)).
The FDA clearance follows successful completion of a Phase 1 trial in healthy volunteers earlier this year. "This IND clearance marks a major milestone for Vasa, underscores the strength of our science and development strategy, and demonstrates exceptional execution," said Artur Plonowski, MD, Chief Executive Officer of Vasa Therapeutics (搜索).
Phase 1c Trial Design and Objectives
The Phase 1c study will assess the safety and tolerability of VS-041 in participants with HFpEF (搜索) and elevated serum endotrophin (搜索) levels. The trial aims to evaluate potential effects of VS-041 on clinical and prognostic biomarkers of HFpEF, including endotrophin, which is associated with excess morbidity and mortality in this patient population.
Data from this study could demonstrate target engagement and support dose selection for future clinical development. "A Phase 1c study of VS-041 is the first step to evaluate prospectively the therapeutic impact of interrupting the generation of endotrophin (搜索)," said Julio Chirinos, MD, PhD, Professor of Medicine in the Cardiovascular Division at the Perelman School of Medicine at the University of Pennsylvania.
VS-041 Mechanism and Preclinical Data
VS-041 is an oral compound discovered and developed by Vasa for the potential treatment of HFpEF (搜索) and other chronic diseases characterized by fibroinflammation, including hypertrophic cardiomyopathy (搜索) and chronic kidney disease (搜索). In preclinical HFpEF models, VS-041 robustly reduces cardiac fibrosis and significantly improves diastolic heart functions.
The compound is demonstrated to inhibit ex-vivo release of endotrophin (搜索) from primary human cardiac fibroblasts. Development of VS-041 was co-funded by the European Regional Development Fund and the Polish National Centre for Research and Development.
Addressing Unmet Medical Need in HFpEF
HFpEF (搜索) is a complex and progressive form of heart failure characterized by stiffening and fibroinflammation of the heart muscle and impaired relaxation despite normal contractile function. The condition affects approximately 3 million individuals in the United States and 10 million globally.
HFpEF (搜索) is characterized by fibroinflammation that is modulated by matrix metalloproteinases (搜索). Currently approved therapies for HFpEF provide clinical improvement but do not result in disease modification and durable improvement upon discontinuation of treatment.
Clinical Significance of Endotrophin
Endotrophin (搜索) is recognized as a strong predictor of outcomes in HFpEF (搜索) and may be an important contributor to its pathophysiology. Chirinos, who also co-leads a Global Heart Failure biomarker consortium, emphasized the potential therapeutic impact of interrupting endotrophin generation in HFpEF patients.
The University of Pennsylvania owns certain patent applications covering diagnostic methods that use plasma and urine proteins to predict outcomes in patients with HFpEF (搜索), highlighting the growing recognition of biomarker-driven approaches in this condition.